Subscribe to NRx Newsletter

PTSD

Dr. Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals is interviewed by RedChip at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL
Feb. 9, 2026
Dr. Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals interview by RedChip at NobleCon21 – Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference

Dr. Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals is interviewed by RedChip at NobleCon21 – Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL

Read More
Aug. 24, 2021
NRx Pharmaceuticals Announces Closing of $30 Million Private Placement

RADNOR, Pa., Aug. 24, 2021 /PRNewswire/ — NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. The Company issued to the investors in the private placement unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 2,727,273 shares of […]

Read More
Aug. 10, 2021
NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021

NRx Advancing Investigational Medicines for Critical COVID-19 and Other Respiratory Conditions, Vaccine to Prevent COVID-19 and Breakthrough Drug for Suicidal Depression and PTSD RADNOR, Pa., Aug. 10, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of NRx, will […]

Read More